GSK to advance mRNA flu vaccine to late-stage trial
(Corrects paragraph 4 to clarify that GSK plans to start more than 20, not 25, late-stage trials in 2026) Sept 1 (Reuters) – GSK said on Tuesday it will advance its mRNA-based seasonal influenza vaccine candidate to a late-stage trial after mid-stage data showed it generated stronger immune response
























